Wikipedia
Search Wikipedia:

July 2017
MonTueWedThuFriSatSun
     12
3456789
10111213141516
17181920212223
24252627282930
31      

Calendar Calendar

Free Hit Counter

Epalrestat effects on diabetic neuropathy

View previous topic View next topic Go down

Epalrestat effects on diabetic neuropathy

Post  kokoblue on Tue Apr 27, 2010 1:53 am

Diabetic neuropathy is one of the most common long-term complications in patients with diabetes mellitus, with a prevalence of 60-70% in the United States. Treatment options include antidepressants, anticonvulsants, tramadol, and capsaicin. These agents are modestly effective for symptomatic relief, but they do not affect the underlying pathology nor do they slow progression of the disease.

Epalrestat is an aldose reductase inhibitor that is approved in Japan for the improvement of subjective neuropathy symptoms, abnormality of vibration sense, and abnormal changes in heart beat associated with diabetic peripheral neuropathy. Unlike the current treatment options for diabetic neuropathy, epalrestat may affect or delay progression of the underlying disease process.

Recently, three aldose reductase inhibitors—Epalrestat, fidarestat, and ranirestat— have been evaluated in placebo-controlled clinical trials. Epalrestat is an aldose reductase inhibitor that is approved in Japan for the improvement of subjective neuropathy symptoms, abnormality of vibration sense, and abnormal changes in heart beat associated with diabetic peripheral neuropathy. It is the only drug available in the aldose reductase inhibitor class and was approved in Japan in 1992.

kokoblue

Posts : 15
Join date : 2010-04-21

View user profile

Back to top Go down

View previous topic View next topic Back to top

- Similar topics

 
Permissions in this forum:
You cannot reply to topics in this forum